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Background: AGS-003 is an autologous immunotherapy prepared from fully matured and optimized monocyte-derived
dendritic cells, which are co-electroporated with amplified tumor RNA plus synthetic CD40L RNA. AGS-003 was evaluated
in combination with sunitinib in an open label phase 2 study in intermediate and poor risk, treatment naïve patients with
metastatic clear cell renal cell carcinoma (mRCC).
Methods: Twenty-one intermediate and poor risk patients were treated continuously with sunitinib (4 weeks on,
2 weeks off per 6 week cycle). After completion of the first cycle of sunitinib, patients were treated with AGS-003 every
3 weeks for 5 doses, then every 12 weeks until progression or end of study. The primary endpoint was to determine the
complete response rate. Secondary endpoints included clinical benefit, safety, progression free survival (PFS) and overall
survival (OS). Immunologic response was also monitored.
Results: Thirteen patients (62%) experienced clinical benefit (9 partial responses, 4 with stable disease); however there
were no complete responses in this group of intermediate and poor risk mRCC patients and enrollment was terminated
early. Median PFS from registration was 11.2 months (95% CI 6.0, 19.4) and the median OS from registration was
30.2 months (95% CI 9.4, 57.1) for all patients. Seven (33%) patients survived for at least 4.5 years, while five (24%)
survived for more than 5 years, including 2 patients who remain progression-free with durable responses for more than
5 years at the time of this report. AGS-003 was well tolerated with only mild injection-site reactions. The most common
adverse events were related to expected toxicity from sunitinib therapy. In patients who had sequential samples available
for immune monitoring, the magnitude of the increase in the absolute number of CD8+ CD28+ CD45RA−
effector/memory T cells (CTLs) after 5 doses of AGS-003 relative to baseline, correlated with overall survival.
Conclusions: AGS-003 in combination with sunitinib was well tolerated and yielded supportive immunologic
responses coupled with extension of median and long-term survival in an unselected, intermediate and poor risk
prognosis mRCC population.
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Renal cell carcinoma (RCC) is an immunologically respon-
sive tumor and until recently, the mainstay for systemic
therapy for advanced metastatic RCC was cytokine-based
immunotherapy with interleukin 2 (IL-2) and interferon
alpha (IFN-α). During the past decade, identification of
critical cellular growth factor pathways in RCC has en-
abled development of drugs targeting the vascular endo-
thelial growth (VEGF) pathway and the mammalian target
of rapamycin (mTOR) complex. Approved VEGF tyrosine
kinase inhibitors (TKIs) and mTOR inhibitors have shown
clinically relevant benefit in phase 3 trials [1]. Although
durable responses are rarely seen with these targeted
agents [1-3], they can be used for a broader spectrum of
patients than cytokines and the clinical benefit as evi-
denced by improvements in both progression-free and
overall survival, primarily in patients with favorable and
intermediate risk profiles, has positively impacted the nat-
ural history of metastatic RCC (mRCC) [4].
In contrast to the VEGF and mTOR inhibitors, durable
and complete responses have been observed with high dose
(HD) IL-2, indicating the importance of immune modula-
tion in this disease process [5]. While 25% may show re-
sponse, only 5-8% of patients experience durable complete
responses. HD IL-2 is, however, associated with significant
toxicity, which has limited this modality to be delivered at
specialized centers in a highly selected and limited popula-
tion of mRCC patients with a high level of cardiopulmonary
fitness [6]. Immune modulation, if it can be delivered with
low toxicity and be applicable to a broader mRCC popula-
tion, would be a desirable therapeutic approach to pursue
in combination with standard targeted therapy.
Dendritic cells (DCs) are a powerful tool for stimulating
cell-mediated immunity by efficient presentation of antigen
to both CD4+ and CD8+ Tcells [7,8]. AGS-003 is an autolo-
gous immunotherapy approach which provides the critical
signals required to generate a patient and tumor specific
adaptive immune response. AGS-003 is prepared ex vivo
from matured monocyte-derived DCs co-electroporated
with the patient's amplified tumor RNA and synthetic
CD40L RNA [9-12]. When administered by intradermal in-
jection, these optimized, RNA-loaded mature DCs are cap-
able of presenting the relevant patient-specific tumor
antigens, via MHC-Class I presentation, to T cells in the
draining lymph node basin. Additionally, CD40 ligation op-
timizes CD8+ T cell induction through production of IL-12
[11,12]. AGS-003 has previously been evaluated as a mono-
therapy [13] in newly diagnosed, intermediate and poor
risk, synchronous mRCC patients and was tolerated well
with no grade 3 or 4 adverse events. In a predominantly
poor risk population, median PFS was 5.5 months and me-
dian overall survival (OS) was 15.7 months, with 23% of pa-
tients surviving for 3.5 to 8 plus years, despite limited use
of any subsequent systemic therapy, including targetedtherapy (T. Logan, A. Amin, V. Cohen, et al. A Phase 1/2
Study of AGS-003, a personalized immunotherapeutic eval-
uated in newly diagnosed metastatic renal cell carcinoma
subjects; In preparation). The use of autologous tumor
RNA for broad tumor antigen presentation by autologous,
mature DCs holds promise as a fully personalized, patient-
specific immunotherapeutic product as it minimizes the
risk of mutant clonal escape with presentation of multiple
target antigens from the autologous tumor sample [14-17].
Sunitinib is the standard of care for first-line treatment
of mRCC. It is particularly attractive for combination ther-
apy with a novel immunotherapeutic approach. Sunitinib
has been shown to elicit a positive modulatory effect on
the immune system through suppression of myeloid-
derived suppressor cells (MDSCs) and T regulatory (Treg)
cells [18,19]. Tumors are infiltrated with Treg cells and
MDSCs that actively inhibit T-cell responses and contrib-
ute to altered immune surveillance in RCC [20,21]. While
targeted therapies such as sunitinib have yielded improved
efficacy over the past decade, durable remissions and
long-term survival are rare, particularly in newly diag-
nosed, intermediate and poor risk metastatic RCC
(mRCC) patients. A recent analysis by the International
mRCC Database Consortium (IMDC) indicates newly di-
agnosed, intermediate and poor risk mRCC patients who
present with the time from diagnosis to initiation of
treatment less than 1 year risk factor (DxTx < 1y), have
an expected median progression-free survival (PFS) of
5.6 months and median overall survival (OS) of
14.7 months, despite treatment with standard targeted
therapy [22]. When treated with sunitinib alone, the ex-
pected percentage of intermediate and poor risk mRCC
patients surviving greater than 30 months is 13% [23].
The Phase 2 study was designed to assess the efficacy
and safety of AGS-003 in combination with sunitinib in
patients with newly diagnosed, intermediate and poor
risk, synchronous mRCC after nephrectomy.
Results
Patients
Of 25 enrolled patients who underwent leukapheresis,
three patients were withdrawn prior to study treatment,
either due to rapid disease progression (n = 1), uncon-
trolled hypertension (n = 1) or withdrawal of consent
(n = 1) (Figure 1). Twenty two patients entered the in-
duction phase and received sunitinib and at least one
dose of AGS-003, including one patient who had en-
rolled in a prior AGS-003 study. This rollover patient
was excluded from efficacy evaluations and included for
safety evaluation only.
Demographics and tumor characteristics for the effi-
cacy population (n = 21) are shown in Table 1. Median
patient age was 56 years (range 22-68), all treated patients
had clear cell mRCC, and the majority were Fuhrman
Study Schema and Patient Flow Diagram
31 Screen Failures
7 non-clear cell 2 poor ECOG status
5 infectious disease status 2 non-RCC
4 withdrew consent 2 other/not categorized
3 non-surgical candidates 1 autoimmune status
2 brain metastases 1 prohibited med use





25 Subjects received 
Leukapheresis
22 Subjects received 
AGS-003 + sunitinib
17 Subjects received 5 or more 
doses of AGS-003




Figure 1 Study Schema and Patient Flow Diagram.
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All study patients presented with synchronous, measur-
able metastatic disease and had a time from diagnosis to
treatment of less than 1 year (mean = 10.8 ± 6.41 weeks).
Patients were classified as intermediate (71%) or poor
(29%) risk according to Memorial Sloan Kettering Cancer
Center (MSKCC) [24] and intermediate (52%) or poor
(48%) risk according to Heng criteria [25].
AGS-003 Production, Characteristics, and Patient Exposure
The median time from leukapheresis to production and
administration of the first AGS-003 dose was 7 weeks.
The median time from nephrectomy/metastasectomy to
first dose was 11 weeks. The median number of AGS-
003 doses administered was 6 (2-15). Nine patients
(43%) received eight or more AGS-003 doses. Eight pa-
tients (38%) had sunitinib dose delays or dose reductionsduring the trial, including one patient who discontinued
sunitinib while on study. Overall, 10 (48%) patients re-
ceived subsequent therapy after progression, including
TKIs (n = 6), chemotherapy (n = 4), mTOR inhibitor
(n = 2), cytokine therapy (n = 1) and investigational im-
munotherapy (n = 1).
Clinical Responses
Tumor Responses
The best overall tumor response per RECIST, after at
least one 6-week cycle of sunitinib, are shown in Table 2.
No complete responses (CRs) were observed. Overall,
43% (9/21) of patients experienced a partial response
(PR) as their best response (2 PRs were observed follow-
ing the initial 6-week cycle of sunitinib). In addition, 4
PRs were observed during induction with AGS-003 plus
sunitinib, while 3 additional PRs developed during the
Table 1 Demographics and Patient RCC Characteristics
Characteristics Patients N = 21








Time from diagnosis to 1st
sunitinib dose, mean weeks (SD)
10.8 (6.41)
ECOG performance status, n (%)
0 15 (71)
1 6 (29)
MSKCC risk [23], n (%)
Favorable (0 risk factors) 0
Intermediate (1-2 risk factors) 15 (71)
Poor (≥3 risk factors) 6 (29)
Heng risk [24], n (%)
Favorable (0 risk factors) 0
Intermediate (1-2 risk factors) 11 (52)
Poor (≥3 risk factors) 10 (48)
Fuhrman nuclear grade, n (%)
Grade 2 5 (24)
Grade 3 9 (43)
Grade 4 7 (33)











Distant Metastasis Staging, n (%)
M1 21 (100)
ECOG = Eastern Cooperative Oncology Group MSKCC =Memorial Sloan
Kettering Cancer Center; n = number of patients; SD = standard deviation.
Table 2 Tumor response data
Best overall response* PR SD PR + SD PD
N (%)
All patients (n = 21) 5 (24) 8 (38) 13 (62) 8 (38)
MSKCC intermediate risk (n = 15) 4 (19) 7 (33) 11 (52) 4 (19)
MSKCC poor risk (n = 6) 1 (5) 1 (5) 2 (10) 4 (19)
Heng intermediate risk (n = 11) 4 (19) 5 (24) 9 (43) 2 (10)
Heng poor risk (n = 10) 1 (5) 3 (14) 4 (19) 6 (29)
*Restaging scans occurred after five doses of AGS-003 and cycles 2-4 of sunitinib.
NOTE: Responses were determined relative to a baseline scan conducted after
nephrectomy and completion of one (1) 6-week cycle of sunitinib.
PD = progressive disease; PR = partial response; SD = stable disease.
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ing combined treatment. Two of these patients continue
on study treatment for more than 5 years at the time of
this report. Additionally, 4 patients experienced stabledisease. The overall clinical benefit rate for the combin-
ation (CR + PR + stable disease [SD]) was 62% (13/21).
Progression-Free Survival
Median PFS (95% CI) was 11.2 months (6.0, 19.4). Based
upon the Heng risk criteria, the median PFS was 5.8
(4.3, 11.2) months for poor risk and 19.4 (7.2, 38.1)
months for intermediate risk patients. The Kaplan-Meier
PFS estimates for all patients and by Heng risk group
are shown in Table 3.
Overall Survival
Median OS (95% CI) for all patients was 30.2 (9.4, 57.1)
months. Based on the Heng risk criteria, the estimated
median OS was 61.9 months (16.3, NE) for intermediate
risk and 9.1 (5.3, 30.2) months for the poor risk patients.
The Kaplan-Meier OS estimates for all patients and by
Heng risk group are shown in Figure 2.
Overall, 52% (11/21) of patients experienced long-term
survival > 30 months. At the time of this report, 7 (33%)
patients are alive more than 4.5 years from study regis-
tration, while 5 (24%) are alive for more than 5 years, in-
cluding two intermediate risk patients who remain
progression-free and continue to receive booster AGS-
003 dosing and reduced-dose sunitinib on a separate
protocol.
Immune Responses
Fourteen of 21 patients received 5 doses of AGS-003,
underwent a subsequent leukapheresis, and had evalu-
able samples for immunologic analyses. Preclinical stud-
ies demonstrated that AGS-003 administration results in
the generation of CD8+CD28+CD45RA− effector mem-
ory CTLs. Previous published work revealed that in vitro
priming with post matured CD40L RNA electroporated
DCs encoding specific target antigen expanded multi-
functional antigen specific CTLs exhibiting an effector
memory phenotype defined by the expression of CD28
and negative for CD45RA expression. Therefore the pri-
mary immune monitoring end point analysis focused on
identifying increases in the numbers of functional CTLs
Table 3 Kaplan-Meier estimates of progression free survival for all patients and for patients in Heng intermediate and
poor risk factor groups*
Patient group Number of patients at risk Median time to
progression or death
Months (95% CI)
Month 0 3 6 9 12 15 18 21 24 27 30 33 36
All patients (n = 21) 21 21 15 12 10 8 7 6 4 4 3 1 1 11.2 (6, 19.4)
Heng intermediate risk group (n = 11) 11 11 11 9 8 6 6 5 4 4 3 1 1 19.4 (7.2, 38.1)
Heng poor risk group (n = 10) 10 10 4 3 2 2 1 1 0 0 0 0 0 5.8 (4.3, 11.2)
*Similar results were obtained for MSKCC intermediate (14.9 months) and poor (5.7 months) risk factor groups.
CI = confidence interval.
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ministration of AGS-003 [11,12]. A CTL was consid-
ered functional if it expressed any of the functional
markers defined by cytokine secretion (IFN-g, TNF-a,
and IL-2), lytic function (CD107a), or proliferated (Brdu).
Figure 3 outlines the gating strategy to detect functional
CD28+/CD45RA- CTLs. Functional CD28+/CD45RA-
CTLs were quantitated prior to systemic therapy (post-
nephrectomy prior to sunitinib) and after 5 doses of
AGS-003 in combination with sunitinib. The baseline
level for each patient was determined by averaging the
absolute number of functional CD28+/CD45RA- CTLs/
ml after in vitro stimulation for the two baseline sam-
ples, one pre- and one post-nephrectomy, both prior to
AGS-003 administration. The absolute numbers of
functional CD28+/CD45RA- CTLs were determined after
the 5th dose of AGS-003. Neither the baseline response
prior to AGS-003 administration (Figure 4A) nor the re-
sponse after the 5th dose of AGS-003 (Figure 4B) corre-
lated with overall survival (Figure 4D). However after the
5th dose, 10 of 14 (71%) patients analyzed displayed an in-
crease in the number of functional CD28+/CD45RA-Figure 2 Overall survival. Kaplan-Meier estimates of overall survival (mon
factor groups. Similar results were obtained for MSKCC intermediate (39.5 mCTLs over baseline (Figure 4C). Furthermore, this change
in the magnitude of the response showed a statistically
significant correlation with the duration of survival (non-
parametric bivariate analysis, Spearman’s ρ = 0.8; p <
0.002). Therefore the detection of newly generated CTLs
are most likely to be tumor antigen-specific following
stimulation with autologous DCs electroporated with au-
tologous amplified tumor RNA. Notably, one patient ex-
hibited prolonged survival in the absence of a detectable
increase in the absolute number of CTLs. Interestingly,
this patient had significant numbers of CTLs at baseline,
prior to AGS-003 initiation.
Safety
Treatment emergent adverse events occurring in five or
more patients are listed in Table 4. Table 4 also shows
the relationship of adverse events to study treatments
(AGS-003, sunitinib or combination). All patients re-
ported at least one event. There were no grade 4 toxicities
reported, and no patient withdrew from the study due to
an adverse event. Nine patients had grade 3 events attrib-
uted to sunitinib treatment; none of these were attributedths) for all patients and by patients in Heng intermediate and poor risk








Figure 3 Representative flow cytometry plots detailing the gating strategy to identify CD28+/CD45RA- CD8 + T cells expressing effector
molecules. The viable CD3+ CD8+ T cells in the lymphoycte gate were identified and futher subgated to analyze CD28 and CD45RA expression on the
Brdu+, IFN-g+ CD107a+ IL-2+ and TNFa+ cells within the CD8+ T cell gate. The number of cellular events in the CD28+/CD45RA- upper left quadrant
were used to determined the absolute number of cells/ml. Identical gates were used for all samples analyzed.
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gent serious adverse events reported (one case each of
bradycardia, constipation, diarrhea, pneumonia, dehydra-
tion, hypocalcemia and urinary retention), that resolved
without sequelae with standard management. No grade 3
or serious adverse event was considered related to AGS-
003. There were no treatment related deaths.
The most frequent AGS-003-related events were mild
(grade 1) injection-site reactions, including erythema (7/
22 patients), induration (5/22), swelling (4/22) pain (3/
22) and pruritus (3/22). No adverse events unique to the
combination of AGS-003 plus sunitinib were reported.
Adverse events reported within 24 hours of a leuka-
pheresis procedure occurred in eleven patients, includ-
ing vomiting in two patients (one of whom also had
nausea and decreased weight), four patients with pain,
three patients with fatigue, one patient with constipation
and nausea, and one patient with muscle spasms andoral paresthesia. All were mild to moderate in severity
and did not preclude further participation nor require
hospitalization.
No evidence of emergent autoimmunity was noted per
laboratory assessments for auto-immune markers. There
were no clinically relevant outcomes for hematology,
biochemistry, and urinalysis laboratory assessments,
physical examinations, vital signs, or ECGs.
Discussion
During the past decade, VEGF-targeted therapies have be-
come standard treatment for advanced RCC. While tar-
geted therapies have yielded improved efficacy, durable
remissions, CRs (<1%) and long-term survival (>30 months)
are rare, particularly in intermediate and poor risk
metastatic RCC (mRCC) patients [25,26]. A recent ana-
lysis by the International mRCC Database Consortium
(IMDC) revealed that newly diagnosed, intermediate
Figure 4 (See legend on next page.)
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Figure 4 Measurement of AGS-003 induced multifunctional CD8+CD28+CD45RA− CTLs and correlation with overall survival. Absolute
number of CD28+/CD45RA- CTLs in response to DCs electroporated with autologous amplified RCC tumor RNA at baseline (A) and after 5 doses of
AGS-003 (B). Increase in the number of CD28+/CD45RA- CTL from baseline to post 5th dose (C). Patients are listed by in increasing order of overall
survival (D). Blue bars ( ) identify intermediate risk patients and red bars ( ) identify poor risk patients. The correlation between the absolute number
of CD28+/CD45RA- CTLs and overall survival was statistically significant by nonparametric bivariate analysis, Spearman’s ρ = 0.8; p < 0.002.
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time from diagnosis to initiation of treatment less than
1 year risk factor (DxTx < 1y), have an expected median
PFS of 5.6 months and median OS of 14.7 months, despite
treatment with standard, sequential targeted therapy [22].
Attempts to improve outcome using combinations of tar-
geted agents including TKIs, mTORs, plus interferon have
been limited due to severe and/or overlapping toxicity
[27-30]. While immune modulation with IL-2 has shown
durable responses, it is limited to a select population of
patients. Therefore, there is a need to identify novel im-
munomodulatory therapies for mRCC.
The rationale to combine sunitinib with AGS-003, a
fully personalized immunotherapy, was based upon the
proven antitumor activity of sunitinib and its potential to
attenuate the immune suppression in the tumor micro-
environment observed in advanced RCC [18,19]. In this
study, AGS-003 was evaluated in combination withTable 4 Treatment emergent adverse events occurring in 5 o
treatment
Adverse event Treatment-Emergent adverse even
All AGS-003 relat
Any 22 (100) 17 (77)
Diarrhea 13 (59) 3 (14)
Fatigue 13 (59) 3 (14)
Nausea 12 (55) 2 (9)
Rash 10 (46) 4 (18)
Decreased weight 9 (41) 1 (5)
Headache 8 (36) 2 (9)
Injection-site erythema 8 (36) 7 (32)
Peripheral edema 8 (36) 0
Dyspnea 7 (32) 0
Vomiting 7 (32) 0
Anorexia 6 (27) 0
Hypertension 6 (27) 1 (5)
Hypothyroidism 6 (27) 0
Hand-foot syndrome 6 (27) 0
Constipation 5 (23) 0
Dehydration 5 (23) 0
Dysgeusia 5 (23) 1 (5)
Injection-site induration 5 (23) 5 (23)
*Events described as possible, probably or definitely related to study drug.
**All AGS-003 related events were Grade 1 or 2 in severity.sunitinib for the treatment of newly diagnosed mRCC pa-
tients with intermediate or poor risk as defined by either
MSKCC or Heng criteria. All patients presented with the
DxTx < 1 yr risk factor and the majority presented with at
least 2, 3 or 4 risk factors. When this study was initially
designed, the primary objective was to determine whether
the addition of AGS-003 to sunitinib could achieve a 20%
complete remission rate. As TKI data matured, it became
evident that sunitinib was rarely if ever associated with
CRs in advanced RCC, even in studies where approxi-
mately one-third of subjects entered with favorable risk
disease [26,31,32]. Based on emerging data and insights
during study conduct, it became evident that the primary
endpoint was inappropriate for this population. Therefore,
further enrollment was stopped. An independent safety
monitoring board established at study start continued to
monitor safety for the duration of the study. Patients
already enrolled continued treatment and follow-up perr more patients and relationships* to study drug
ts N = 22 Number of patients (%)
ed** Sunitinib related Combination related
22 (100) 12 (55)
11 (50) 3 (14)
12 (55) 2 (9)
11 (50) 2 (9)
9 (41) 5 (23)
5 (23) 1 (5)





5 (23) 1 (5)
6 (27) 1 (5)




5 (23) 1 (5)
0 1 (5)
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and safety. These endpoints were deemed to be much
more instructive for future AGS-003 development efforts
in similar, newly diagnosed intermediate and poor risk
mRCC patients.
In addition to limited expectations for durable complete
remissions with targeted therapies such as sunitinib, these
treatments also appear to exert both cytotoxic and
cytostatic effects which complicate response assess-
ment, particularly when combined with immunotherapy.
RECIST-based criteria used traditionally for evaluating re-
sponse to cytotoxic agents may therefore not be adequate
or helpful to evaluate clinically relevant outcomes with
targeted therapies alone, since they may induce necrosis
with minimal change in size with conventional imaging
[33]. Yet another layer of complexity regarding re-
sponse evaluation is added by the immunotherapy com-
ponent used in combination with sunitinib in this
study. Observations with immunotherapy in patients with
metastatic melanoma treated with agents such as ipilimu-
mab, led to the development of immune response cri-
teria that showed disease stability translates into clinical
benefit. Delayed responses were noted even after initial
increases in tumor burden [34]. Therefore, disease
stabilization and overall survival may be more appropri-
ate measures of clinical benefit with new immunothera-
peutic modalities such as AGS-003. This is further
supported by the proportion of melanoma patients
treated with ipilimumab demonstrating durable, long
term overall survival at a follow-up of 5 to 6 years [35].
In this study, the median PFS for all subjects was
11.2 months and the median OS was 30.2 months,
which represents a near doubling of expected survival in
this group of patients. The median OS was estimated to
be more than 5 years at 61.9 months for the 11 patients
classified as Heng intermediate risk (1-2 risk factors
[22]) which are encouraging and suggest that combined
targeted therapy plus immunotherapy may have a sig-
nificant impact on survival outcomes in intermediate
risk mRCC patients.
Fifty-two percent of the evaluable patients receiving AGS-
003 plus sunitinib demonstrated long term (>30 month) sur-
vival. This compares favorably with historical analysis indi-
cating approximately 13% of intermediate and poor risk
mRCC patients treated with sunitinib alone survive for
> 30 months, which has been defined as long-term in
the advanced RCC setting [25]. In addition, a third of
the patients on this study were alive and in follow-up or
continuing treatment with AGS-003 plus sunitinib for
more than 4.5 years. As of June 2014, 24% (5/21) had
survived for more than 5 years after study initiation, in-
cluding 2 patients in prolonged partial remissions who
continue AGS-003 booster dosing plus reduced-dose
sunitinib.The intended mechanism of action of AGS-003 is to
induce CD8+ CD28+ CD45RA− CTLs against patient-
specific tumor antigens. Under normal conditions, acti-
vated helper CD4+ T cells up-regulate CD40L and
physically interact with DCs resulting in effective CD8+
cytotoxic T cell responses [36]. However, mRCC patients
are immunosuppressed due to local and systemic influ-
ences of the tumor cells and display both DC and CD4+
helper T cell dysfunction [19,37-39]. AGS-003 ad-
dresses the immune dysfunction of the host by co-
electroporation of RNA encoding CD40L into the
ex vivo-prepared DCs to simulate the presence of CD4+
T cell help via the intracellular ligation of endogenous
CD40 within the DCs. This also results in the secretion
of IL-12 from the DCs, a requirement for the gener-
ation of T cell responses [11]. Additional functionality
was engineered into AGS-003 via the novel method by
which the cells are matured. Rather than employing the
traditional ‘cytokine cocktail’ method [40], sequential
cytokine exposure was employed which results in DCs
that primarily induce CTL generation [10]. This func-
tionality is important because memory T cell responses
have been associated with good clinical outcome in pa-
tients with solid tumors [41-43]. Collectively, these prop-
erties allow AGS-003 to generate anti-tumor memory T
cell responses within the immunosuppressed patient.
The increase in the absolute number of CTLs between
baseline and fifth dose of AGS-003 was a statistically sig-
nificant correlate to survival, even with this small num-
ber of patients (Figure 4C and D). The number of
tumor-reactive CTLs prior to (baseline) and after the 5th
dose of AGS-003 did not correlate with survival (Figure 4A
and B). This suggests that the pre-existing T cells were not
contributing to clinical outcome and only the newly gen-
erated, effector memory CTLs induced by AGS-003 ad-
ministration were functionally significant. A positive
increase in the magnitude of the induced CTL response is
indicative of the induction of an antigen specific CTL re-
sponse following AGS-003 administration. It is to be
noted that these data were obtained prospectively since
the clinical outcomes were not known at the time the
immunologic assessment was carried out. The prognos-
tic value of absolute changes in CTL numbers in re-
sponse to AGS-003 as an early biomarker for overall
survival is being prospectively assessed in the ongoing
pivotal ADAPT Phase 3 clinical trial (Clinical Trial
Registry #NCT01582672).
In clinical practice, the most common side effects of
sunitinib treatment include fatigue/asthenia, anorexia/
loss of appetite, hypothyroidism, hand-foot syndrome,
stomatitis/taste changes, diarrhea/abdominal pain, mye-
losuppression, and hypertension [44]. The most com-
mon adverse events in the present study were consistent
with those reported with sunitinib alone in advanced
Amin et al. Journal for ImmunoTherapy of Cancer  (2015) 3:14 Page 10 of 13RCC. Adverse events attributed to AGS-003 were pri-
marily mild injection-site reactions, which occurred in
about half of the patients. No adverse events unique to
the combination of AGS-003 plus sunitinib were re-
ported. No grade 4 events occurred during the study
and no grade 3 events considered related to AGS-003
therapy. These safety results are noteworthy, since many
newly approved targeted therapies are associated with
serious side effects (gastrointestinal, skin, and vascular
events) that affect morbidity and mortality and limit the
ability to combine these newer treatments [45].
Conclusion
When compared to outcomes and benchmarks estab-
lished with targeted therapy, the addition of AGS-003 to
sunitinib in an unselected, intermediate and poor risk
mRCC patient population was associated with a doubling
of expected survival, encouraging long-term and 5-year
overall survival, and an excellent safety profile. In addition,
the target effect of AGS-003, an expansion of effector
memory CTLs, was observed after 5 doses and correlated
to prolonged survival. These encouraging findings support
the ongoing phase 3, randomized ADAPT study, which
has been designed to compare the addition of AGS-003
with standard surgery and targeted drug therapy to stand-
ard surgery and targeted drug therapy alone in newly diag-
nosed, intermediate and poor risk mRCC patients.
Methods
The trial was a single-arm, open-label phase 2 study con-
ducted from January 2008 to February 2012 at 10 centers
in North America (Clinical Trial Registry #NCT00678119).
Treatment was administered according to International
Conference on Harmonization Good Clinical Practice
guidelines and applicable local regulatory requirements
and laws, and the clinical protocol was approved by in-
stitutional review boards or independent ethics com-
mittees at each study center. All patients provided
written informed consent.
Patients
Men and women at least 18 years of age with newly or
recently diagnosed synchronous, metastatic RCC (mRCC)
and predominantly clear cell tumor were enrolled if they
had no prior nephrectomy or had a recent nephrectomy,
but had at least one accessible metastatic lesion for metas-
tasectomy. Inclusion criteria required measurable meta-
static disease per Response Evaluation Criteria in Solid
Tumors (RECIST) [46] and Eastern Cooperative Oncology
Group (ECOG) performance status 0 or 1. All patients in-
cluded had a time from diagnosis to treatment of less than
1 year (DxTx < 1 yr).
Patients were required to be candidates for sunitinib
therapy and were required to have adequate end organfunction. Patients with brain metastases, uncontrolled
hypertension, Type 1 diabetes, active autoimmune dis-
ease, or previous systemic therapy for advanced RCC
were excluded.AGS-003 Production
AGS-003 was manufactured at a centralized GMP com-
pliant facility (Argos Therapeutics, Durham, NC). Fol-
lowing screening and consent, autologous tumor total
RNA was isolated from nephrectomy or metastasectomy
tissue samples and messenger RNA was amplified using
RT/PCR and in vitro transcription technologies as previ-
ously described [47]. CD40L RNA was manufactured
using in vitro transcription and a post-transcriptional
capping method [48]. Patients had leukapheresis at the
clinical site’s donor center using a COBE Spectra®
Leukapheresis System (Gambro BCT, Lakewood, CO).
Monocytes were cultured in AIM-V media with 800 U/
mL granulocyte macrophage-colony stimulating factor
(Berlex) and 1000 U/mL IL-4 (R&D Systems) to generate
immature DCs that were then matured using 20 ng/mL
tumor necrosis factor alpha (TNF α) (R&D Systems)/1000
U/mL IFN-γ (InterMune)/1 μg/mL prostaglandin E2
(Sigma). Mature DCs were electroporated with the amplified
tumor RNA and CD40L RNA using a post-maturation elec-
troporation protocol [10].
The final AGS-003 product was formulated as 1.4 ×
107 DC/0.7 mL in 80% autologous plasma, 10% dex-
trose (50% w/v) (Hospira), and 10% DMSO (Sigma) and
cryopreserved in liquid nitrogen vapor phase. Thawed
samples of final product were assessed for sterility,
mycoplasma, endotoxin, and viability prior to release
for clinical use.Treatment
The treatment schedule is illustrated in Figure 1. Prior to
initiation of AGS-003 therapy, patients initiated sunitinib
therapy on a standard, repeating 6-week cycle of 50 mg
daily for 4 weeks followed by 2 week rest. Dose modifica-
tions (reductions, delays, and/or discontinuation due to
toxicity) for sunitinib were permitted per standard labeling
throughout study directed treatment. AGS-003 was ad-
ministered prior to the initiation of the second 6-week
cycle of sunitinib (week 6). Each dose of AGS-003 con-
sisted of 1.2 × 107 DCs delivered as three intradermal in-
jections of 0.2 mL (0.6 mL total) to the axillary lymph
node basin. AGS-003 treatment continued every 3 weeks
for a total of five doses (induction phase) in combination
with sunitinib. Following induction, AGS-003 was admin-
istered every 12 weeks along with standard sunitinib
(booster phase). Treatment was continued until disease
progression, intolerable toxicity to standard of care, or
end of study. Patients who continued to benefit from
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rolled over to companion AGS-003 trials.
Tumor Response Assessments
Tumor measurements were assessed pre-nephrectomy/
metastasectomy, after one cycle of sunitinib prior to
the initiation of AGS-003, and after the fifth dose of
AGS-003. During booster treatment, imaging occurred
every 12 weeks.
Immune Response Assessments
Preparation of blood draw samples for immune monitor-
ing by multi-color flow cytometry. Frozen PBMCs proc-
essed by ficoll density gradient separation from whole
blood draws were collected for immune monitoring prior
to surgery, prior to initiation of sunitinib, and at two
points after initiation of AGS-003, following the third and
fifth AGS-003 dose (Figure 1). PBMCs were thawed and
rested overnight in X-Vivo 15 supplemented with 10%
Human AB serum. After overnight rest PBMCs were la-
beled with BRDU (bromodeoxyuridine) to track T-Cell
proliferation. A leukapheresis for immune monitoring was
collected after the fifth dose and autologous DC targets
for in vitro stimulation were prepared from DCs co-
electroporated with CD40L RNA and autologous RCC
tumor RNA for each evaluable subject. Autologous
cultures containing DCs and PBMCs were setup and in-
cubated at 37°C for 6 days. On day 6, cultures were re-
stimulated with autologous DCs prepared as stated
above and anti-CD107a antibody was added to each
tube and incubated at 37°C for 5 hours in the presence
of Brefeldin A (BD Biosciences). After incubation, cells
were stained for viability using annexinV and a viability
dye (Invitrogen), which permits selection of viable cells,
followed by surface staining with specific antibodies for
detection of CD28, CD45RA, CD3, and CD8 expres-
sion. After surface staining, cells were fixed with 4% BD
Cytofix and stored overnight in BSA staining buffer at
4°C. The following day, the cells were permeabilized
and DNase treated for 1 hour at 37°C using reagents in-
cluded in the BRDU staining kit (BD biosciences). Intra-
cellular staining for IFN-γ, TNF-α, IL-2, and BRDU were
performed. After staining, cells were washed and diluted
in 500 μl BSA buffer and transferred to a BD TruCount
Tube for acquisition on a BD LSRII cytometer. 400,000-
600,000 events were collected per sample. Number of
cells/ml was calculated using the following formula; (num-
ber of cellular events collected/number of beads collected)
x (bead concentration)/collected volume) × 1000.
Gating strategy to define the absolute numbers of
functional CD28+/CD45RA- CTLs
The absolute number of cells expressing IFN-g, IL-2,
TNF-a, CD107a or BRDU were first identified in theCD8+ viable cell gate. Within each gate identifying the
number of IFN-g, IL-2, TNF-a, CD107a or BRDU positive
cells, the number of cells positive for CD28 and negative
for CD45RA were subsequently determined (Figure 3). To
determine the total number of functional CD28+/CD45RA-
CTLs, the numbers of CD28+/CD45RA- CTLs having any
function were added together to determine the absolute
number of functional CD28+/CD45RA- CTLs. This
was done for each subject at each indicated time point,
pre and post 5th dose AGS-003 administration. To define
the overall magnitude for the response to autologous
AGS-003 product the value determined pre AGS-003 ad-
ministration was subtracted from the value determined
after the 5th AGS-003 dose administration to calculate the
absolute change in CTLs between these two time points.
Endpoints
The efficacy and safety population consisted of all study
subjects who received at least one AGS-003 dose. One
patient enrolled on a previous AGS-003 monotherapy
study was included in the safety, but not efficacy popula-
tion because of prior AGS-003 exposure.
The primary endpoint was the CR rate as defined by
RECIST v1.0 [46]. Secondary endpoints included PFS, OS,
immune response and clinical benefit (CR, PR or SD).
PFS was calculated from the date of registration. The
progression time of patients who did not progress at the
time of final analysis or who withdrew early without
documentation of progression were censored at the time
of the last tumor evaluation. OS was calculated from
the time of registration until death. The time of death
for patients alive at the time of final analysis or lost to
follow-up was censored at the last date they were
known to be alive. Patients who rolled over to subse-
quent, companion AGS-003 trials were routinely moni-
tored for survival.
Safety was assessed by monitoring the incidence of ad-
verse events, laboratory assessments, localized injection-site
reactions, and changes in size, tenderness, or inflammation
of draining lymph nodes throughout the study. Adverse
events were assessed by investigators as being possibly,
probably, definitely or not related to AGS-003, sunitinib, or
the combination, and graded for severity according to the
NCI Common Terminology Criteria for Adverse Events
(CTCAE) v3.0. Changes from baseline values in clinical la-
boratory tests and changes in physical examinations, vital
signs, and electrocardiograms (ECGs) were determined
after study drug dosing. Evaluation for autoimmune
reactions was determined by assessing clinical signs and
symptoms (i.e., rash, cytopenias, and arthralgias) and
by laboratory assessments (i.e., anti-nuclear antibody,
rheumatoid factor, anti-double stranded DNA antibody,
total hemolytic complement, anti-thyroid antibody, indir-
ect Coombs test).
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The study was designed to enroll approximately 50 pa-
tients in order to have a sufficient number of patients
who would be eligible to initiate combined AGS-003
plus sunitinib treatment and be evaluable for the assess-
ment of primary and secondary endpoints. The planned
analysis for the primary endpoint (complete response
rate) required a total 38 evaluable and treated patients
for 90% power to detect a CR rate of 20% versus the null
rate of 5%, with a type-I error of 5%. No favorable risk
patients were enrolled and nearly half of the evaluable
patients had 3 or more RCC risk factors (i.e., poor risk)
at the time of diagnosis. Study enrollment was stopped
early when the sponsor concluded that the initial statis-
tical design and expectations of complete response was
inappropriate in the enrolled population of intermediate
and poor risk patients. Rather than amend the protocol
to a more appropriate primary endpoint such as overall
survival, the decision was made to terminate further en-
rollment, to assess appropriate secondary endpoints, and
to plan for a larger randomized study in a similar, inter-
mediate and poor risk mRCC patient population. Prior
to early termination of enrollment, twenty-five patients
were recruited for study participation.
Response was assessed per RECIST v1.0, however the
planned statistical analyses for the primary endpoint
were not performed due to the limited enrollment to the
study. PFS and OS analyses were performed using the
Kaplan-Meier method with two-sided 95% CIs for
the medians. SAS version 9.2 and SPLUS version 6.2
were used for statistical analyses. Proc LIFETEST was
used for Kaplan-Meier analyses. Relationship between
clinical outcome and immune monitoring was analyzed
using JMP version 10.0.0.
ECG, vital signs, body weight, and clinical laboratory
data (actual values and changes from baseline at each
assessment time point) were summarized with descrip-
tive statistics. Laboratory results were evaluated based
on laboratory-specified reference ranges and investiga-
tor determinations of clinical significance for abnormal
results.
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